Bristol Myers Squibb cancer drug doubles progression-free survival in trial

Bristol Myers Squibb's cancer drug doubled survival time without disease progression in a trial, according to reports. The company is also expanding its partnership with Tempus AI, which licenses oncology data to support drug development.

Detected & updated continuously · Source: Nebula